Chugai Pharmaceutical reports vamikibart data: stock pre-market at EUR 34.09
Published on 10/14/2026 at 07:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical update and trading context
- Chugai Pharmaceutical published its vamikibart update on October 13, 2026.
- Chugai stock trades pre-market at EUR 34.09 at 7:51 a.m. CEST at Lang & Schwarz on October 14, 2026.
- The reported clinical results covered Week 52.
- Approximately two-thirds of patients entering as-needed dosing after Week 16 required no retreatment.
Chugai Pharmaceutical said on October 13, 2026, that Roche had announced one-year data from the Phase III MEERKAT and SANDCAT studies of vamikibart in uveitic macular edema. The company reported sustained improvements in vision and reductions in macular thickness through Week 52. Chugai Pharmaceutical published the update.
Pre-market trading
Chugai Pharmaceutical stock was at EUR 34.09 at Lang & Schwarz at 7:51 a.m. CEST on October 14, 2026. The displayed bid was EUR 33.90 and the ask was EUR 34.28. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.
Clinical update
The reported results said that approximately two-thirds of patients who entered the as-needed dosing period after Week 16 required no retreatment. Among patients who did require retreatment, most needed only one additional injection. Roche also reported a consistent safety profile through Week 52. The company release directed readers to Roche's media announcement for further details.
What matters today
Chugai's company update is dated October 13, 2026. The clinical results covered Week 52. Approximately two-thirds of patients entering as-needed dosing after Week 16 required no retreatment. Chugai's release provided the company-specific details.
Market context: Market report Nikkei 225.
